We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What Analyst Projections for Key Metrics Reveal About Stryker (SYK) Q3 Earnings
Read MoreHide Full Article
Wall Street analysts expect Stryker (SYK - Free Report) to post quarterly earnings of $3.14 per share in its upcoming report, which indicates a year-over-year increase of 9.4%. Revenues are expected to be $6.04 billion, up 10% from the year-ago quarter.
The consensus EPS estimate for the quarter has been revised 0.1% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
With that in mind, let's delve into the average projections of some Stryker metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts' assessment points toward 'Net Sales by Business- MedSurg and Neurotechnology' reaching $3.83 billion. The estimate suggests a change of +18.8% year over year.
It is projected by analysts that the 'Net Sales by Geography- Orthopaedics' will reach $2.21 billion. The estimate points to a change of -2.7% from the year-ago quarter.
The average prediction of analysts places 'Net Sales by Geography- Orthopaedics- Hips' at $452.98 million. The estimate points to a change of +7.9% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Net Sales by Geography- Orthopaedics- Other' of $200.77 million. The estimate points to a change of +58.1% from the year-ago quarter.
According to the collective judgment of analysts, 'Net Sales by Geography- International' should come in at $1.50 billion. The estimate points to a change of +8.5% from the year-ago quarter.
The combined assessment of analysts suggests that 'Net Sales by Geography- United States' will likely reach $4.54 billion. The estimate points to a change of +10.5% from the year-ago quarter.
Based on the collective assessment of analysts, 'Net Sales by Geography- Orthopaedics- United States' should arrive at $1.52 billion. The estimate points to a change of -5.1% from the year-ago quarter.
The consensus estimate for 'Net Sales by Geography- Orthopaedics- Trauma and Extremities- United States' stands at $707.27 million. The estimate indicates a year-over-year change of +13.9%.
Analysts forecast 'Net Sales by Geography- Orthopaedics- Knees- United States' to reach $444.33 million. The estimate points to a change of +6.6% from the year-ago quarter.
Analysts expect 'Net Sales by Geography- Orthopaedics- Hips- United States' to come in at $277.52 million. The estimate suggests a change of +8.4% year over year.
The consensus among analysts is that 'Net Sales by Geography- MedSurg and Neurotechnology- Neuro Cranial- International' will reach $141.79 million. The estimate suggests a change of +89.1% year over year.
Analysts predict that the 'Net Sales by Geography- MedSurg and Neurotechnology- Neurovascular- International' will reach $245.41 million. The estimate suggests a change of +18% year over year.
Over the past month, Stryker shares have recorded returns of +3.5% versus the Zacks S&P 500 composite's +2.5% change. Based on its Zacks Rank #3 (Hold), SYK will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
What Analyst Projections for Key Metrics Reveal About Stryker (SYK) Q3 Earnings
Wall Street analysts expect Stryker (SYK - Free Report) to post quarterly earnings of $3.14 per share in its upcoming report, which indicates a year-over-year increase of 9.4%. Revenues are expected to be $6.04 billion, up 10% from the year-ago quarter.
The consensus EPS estimate for the quarter has been revised 0.1% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
With that in mind, let's delve into the average projections of some Stryker metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts' assessment points toward 'Net Sales by Business- MedSurg and Neurotechnology' reaching $3.83 billion. The estimate suggests a change of +18.8% year over year.
It is projected by analysts that the 'Net Sales by Geography- Orthopaedics' will reach $2.21 billion. The estimate points to a change of -2.7% from the year-ago quarter.
The average prediction of analysts places 'Net Sales by Geography- Orthopaedics- Hips' at $452.98 million. The estimate points to a change of +7.9% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Net Sales by Geography- Orthopaedics- Other' of $200.77 million. The estimate points to a change of +58.1% from the year-ago quarter.
According to the collective judgment of analysts, 'Net Sales by Geography- International' should come in at $1.50 billion. The estimate points to a change of +8.5% from the year-ago quarter.
The combined assessment of analysts suggests that 'Net Sales by Geography- United States' will likely reach $4.54 billion. The estimate points to a change of +10.5% from the year-ago quarter.
Based on the collective assessment of analysts, 'Net Sales by Geography- Orthopaedics- United States' should arrive at $1.52 billion. The estimate points to a change of -5.1% from the year-ago quarter.
The consensus estimate for 'Net Sales by Geography- Orthopaedics- Trauma and Extremities- United States' stands at $707.27 million. The estimate indicates a year-over-year change of +13.9%.
Analysts forecast 'Net Sales by Geography- Orthopaedics- Knees- United States' to reach $444.33 million. The estimate points to a change of +6.6% from the year-ago quarter.
Analysts expect 'Net Sales by Geography- Orthopaedics- Hips- United States' to come in at $277.52 million. The estimate suggests a change of +8.4% year over year.
The consensus among analysts is that 'Net Sales by Geography- MedSurg and Neurotechnology- Neuro Cranial- International' will reach $141.79 million. The estimate suggests a change of +89.1% year over year.
Analysts predict that the 'Net Sales by Geography- MedSurg and Neurotechnology- Neurovascular- International' will reach $245.41 million. The estimate suggests a change of +18% year over year.
View all Key Company Metrics for Stryker here>>>Over the past month, Stryker shares have recorded returns of +3.5% versus the Zacks S&P 500 composite's +2.5% change. Based on its Zacks Rank #3 (Hold), SYK will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .